Skip to content
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP

Twist Bioscience Corp. TWST

9 fiscal years on record · USD · FY2025 reported · SEC filings only
$376.6M
▲ 20.3% YoY
$-77.7M
$-75.6M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Twist Bioscience Corporation has developed a DNA synthesis platform that manufactures synthetic DNA by writing DNA on a silicon chip. It sells its products and services to more than 3,800 customers across a broad range of industries. In fiscal year 2025, the company reported $376.6 million in revenue, including $215.1 million from the healthcare sector, $93.2 million from the chemicals/materials sector, $65.9 million from the academic research sector and $2.4 million from the food/agriculture sector. It manufactures its products at facilities in South San Francisco, California and Wilsonville, Oregon. As of September 30, 2025, it had 979 employees. As of September 30, 2025, it had signed 442 revenue-generating partnerships. It generates revenue through synthetic biology and NGS tools product lines, as well as biopharma services for antibody discovery, optimization and development.

Written from the business description in Twist Bioscience Corporation's annual report to the U.S. Securities and Exchange Commission, filed 17 November 2025. Every sentence was checked against that document before publication.

Growth

USD 376.6M
Revenue, FY2025 · full 9-year series below
Revenue $M Net income $M
FY2025 · Revenue 376.6 · Net income -77.7
150M300M-100M-200M
2017202020232025
Compound annual growth
+22.8%
+33.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +33.1% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−21 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -36.2% · Net -20.6%
-200%-400%
201720212025
ROE
FY2025 · ROE -16.4%
-20%-40%
201720212025
Three returns, three denominators.

Each USD of equity lost 16 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -75.6
-100M-200M
201720212025

Total assetsUSD 641.9M
EquityUSD 473.0M
CashUSD 183.0M
Current ratio3.64×

Equity funds 74% of total assets.

The 9-year record

9 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
TWST, 9-year financial record
Metric 202520242023202220212020201920182017
Revenue $B0.40.30.20.20.10.10.10.00.0
Operating income $B−0.1−0.2−0.2−0.2−0.2−0.1−0.1−0.1−0.1
EBITDA $B−0.1−0.2−0.2−0.2−0.1−0.1−0.1−0.1−0.1
Income tax $B0.00.00.0−0.0−0.00.00.00.00.0
Net income $B−0.1−0.2−0.2−0.2−0.2−0.1−0.1−0.1−0.1
Free cash flow $B−0.1−0.1−0.2−0.2−0.1−0.2−0.1−0.1−0.1
EPS, diluted $−1.30−3.60−3.60−4.04−3.15−3.57−3.92−25.51−24.49
Dividend / sh $◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————
ROE %−16.4−38.1−29.0−31.8−33.2−57.3———
Shares out B0.060.060.060.060.050.050.030.00◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 35 reconciliationsAUDITED

Reconciled in 9 of the 9 fiscal years we could check. 22 checks were skipped: the balance sheet is not tagged before 2018. 10 checks were skipped: EPS is not tagged before 2017. 10 checks were skipped: revenue is not tagged before 2017.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsSeptember 30
Data on record since2016

Share this section

Download image